Xeris Biopharma: Undervalued Given The Potential Of Its Drug Portfolio [Seeking Alpha]
Xeris Biopharma Holdings, Inc. (XERS)
Last xeris biopharma holdings, inc. earnings: 3/11 06:00 am
Check Earnings Report
Company Research
Source: Seeking Alpha
XERS delivered strong Q4 results: GAAP EPS of $0.06, 43% revenue growth to $85.1M, and initial FY26 guidance above consensus at $375–$390M. XP-8121, XERS's once-weekly levothyroxine candidate, is set for Phase 3 study in 2026 with peak sales potential of $1–$3B, underpinning valuation upside. An analysis around Xeris Biopharma Holdings follows in paragraphs below. Looking for a helping hand in the market? Members of The Biotech Forum get exclusive ideas and guidance to navigate any climate. Learn More » iQoncept/iStock via Getty Images Shares of endocrine and neurological concern Xeris Biopharma Holdings ( XERS did not react much to a CRL received by rival Corcept Therapeutics' ( CORT relacorilant on December 31, 2025. Approval would likely have meant a meaningful More on my IG service Live Chat on The Biotech Forum sees frequent discussion of specific covered call trades. To see what covered call trades I am currently executing along with a model portfolio of attractiv
Show less
Read more
Impact Snapshot
Event Time:
XERS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XERS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XERS alerts
High impacting Xeris Biopharma Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
XERS
News
- Xeris Biopharma Holdings Inc (XERS) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... [Yahoo! Finance]Yahoo! Finance
- Xeris Biopharma Holdings, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]Yahoo! Finance
- Xeris Biopharma (XERS) had its "buy" rating reaffirmed by HC Wainwright. They now have a $10.00 price target on the stock.MarketBeat
- Xeris Biopharma Holdings, Inc. (XERS) Q4 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Xeris Biopharma: Q4 Earnings Snapshot [Yahoo! Finance]Yahoo! Finance
XERS
Earnings
- 3/2/26 - Beat
XERS
Sec Filings
- 3/2/26 - Form 144
- 3/2/26 - Form S-8
- 3/2/26 - Form 10-K
- XERS's page on the SEC website